EcoDrugPlus

Cytochrome P450 3a29-Like

Ensembl ID : ENSMMNG00015001865
Gene Symbol: LOC114894199
2 Cross references
643 Possible Orthologues:

Cytochrome P450 3a29-Like

Ensembl ID : ENSMMNG00015002083
Gene Symbol: LOC114894197
2 Cross references
652 Possible Orthologues:

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSMMNG00015013335
Gene Symbol: CYP17A1
1 Cross references
210 Possible Orthologues:

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSMMNG00015014781
Gene Symbol: CYP26A1
3 Cross references
207 Possible Orthologues:

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSMMNG00015017158
Gene Symbol: CYP46A1
3 Cross references
259 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSMMNG00015015500
Gene Symbol: DGAT1
3 Cross references
260 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSMMNG00015003182
Gene Symbol: DHODH
1 Cross references
173 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSMMNG00015007761
Gene Symbol: DPYD
3 Cross references
220 Possible Orthologues:

Dipeptidyl Peptidase 4

Ensembl ID : ENSMMNG00015007050
Gene Symbol: DPP4
3 Cross references
282 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSMMNG00015004981
Gene Symbol: DDR2
1 Cross references
265 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSMMNG00015008077
Gene Symbol: DRD1
3 Cross references
261 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSMMNG00015018913
Gene Symbol: DRD2
3 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).